There were patients in our study with metastatic HR-positive/HER2-negative breast cancer, resistant to endocrine therapy, that derived benefit from IO plus chemotherapy including one patient with a durable response (PFS > 9 months) and 5 patients with PFS > 6 months. The gene discussed is ERBB2; the disease is breast cancer.